Replies to post #44776 on Sunshine Biopharma Inc (SBFM)

[EOT]

INITIAL STUDIES.....


Sunshine Biopharma's Adva-27a is 16-times more effective at killing multidrug resistant breast cancer cells


“”Multidrug Resistant Breast Cancer cell line. Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro. The results of the study showed that Adva-27a is 16-times more effective at killing Multidrug Resistant Breast Cancer cells than Etoposide, the current commonly used drug.“”


NEWS PROVIDED BY
Sunshine Biopharma Inc.
Jul 11, 2011, 08:30 ET
MONTREAL, July 11, 2011 /PRNewswire/ - Sunshine Biopharma Inc. (OTCBB: SBFM), a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a detailed cytotoxicity study of its lead compound, Adva-27a, in MCF-7/MDR, a Multidrug Resistant Breast Cancer cell line. Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro. The results of the study showed that Adva-27a is 16-times more effective at killing Multidrug Resistant Breast Cancer cells than Etoposide, the current commonly used drug. In addition, data generated by the study revealed that Adva-27a is unaffected by the molecular machinery which are responsible for making cancer cells resistant to drugs.

"These findings are remarkable", said Dr. Steve N. Slilaty, Sunshine's President and CEO. He added, "Cancer cells become resistant to anti-tumour drugs by overproducing a protein called P-Glycoprotein. Encoded by the ABCB1 gene (also called the MDR1 gene), P-Glycoprotein is a trans-membrane enzyme that binds and transports drugs to the outside of cancer cells thereby making them resistant. P-Glycoprotein pumps out most, if not all, antineoplastics including doxorubicin, vinblastine, gemcitabine, etoposide, paclitaxel, etc. Our data showed that P-Glycoprotein cannot bind and transport Adva-27a. This is extremely interesting with far reaching scientific and drug development implications. Previously unavailable, Adva-27a now offers a chemical structure which can be used as a basis for studying the mechanism of action of P-Glycoprotein as well as for the development of new drugs which can overcome the resistance caused by P-Glycoprotein and similar enzymes".

[EOT]

DD on just what we have here. I’m comparing the #1 cancer treatment used today....
ETOPOSIDE compared to Adva-27a...
CHECK THIS OUT!!!!


ETOPOSIDE...

https://www.apexbt.com/etoposide.html

Background
Etoposide (VP-16) is the first agent recognized as a topoisomerase II inhibitor of anticancer drug with IC50 of 59.2 µM.

That’s..... 59.2







http://www.sunshinebiopharma.com/assets/press/Pr_Rel_TopoII_Inhibition_at_red_V3_Final.pdf

SBFM initial 2011 studies state WE are at 13.7..



“An IC50 of 13.7 micromolar indicates that Adva-27a is an excellent inhibitor of Topoisomerase II”, said Dr. Steve N. Slilaty, Sunshine’s President and CEO. “Compounds displaying IC50’s in the 75 to 100 micromolar range cannot be developed into effective drugs as the amounts which would have to be administered to patients would be too toxic. We are delighted to find that our compound has such low IC50. This is a significant milestone in our continued development of Adva-27a”, he added.



https://www.sunshinebiopharma.org/anticancer-research

WOW....now down to 1.44

Adva-27a is an excellent inhibitor of Topoisomerase II
with an IC50 of only 13.7 micromolar (this number has recently been reduce
to 1.44 micromolar as a result of resolving the two isomeric forms
of Adva-27a).



I believe this was the key that triggered the beginning of clinical trials last month

Feb 2019...
http://www.sunshinebiopharma.com/assets/press/Press_Release_Notice_of_Allownace_20190204_V3_Final.pdf

The new patent (US Patent Application Number 20150353573) contains new subject matter





I believe that the 16x more effective than ETOPOSIDE.....
has likely increased dramatically!!